Medical cannabis in Switzerland — the complete 2026 guide
Cannabis medicines differ in their active ingredients, authorisation and uses. Since August 2022, medical prescribing no longer requires an FOPH exemption; treatment and reimbursement still need individual assessment. This overview explains the difference between legal status, evidence of benefit and safety.
Key facts at a glance
- Exceptional FOPH permit
- No longer required for medical prescribing since August 2022
- Effectiveness
- Depends on the medicine, condition and outcome studied
- Basic insurance
- Check the medicine, indication and reimbursement rules
- Data collection
- Reporting has exceptions; records are stored in coded form
- Fitness to drive during treatment
- Prescribed treatment: ability to drive requires individual assessment
The legal framework since August 2022
Since 1 August 2022, doctors no longer need an exceptional FOPH permit to prescribe cannabis medicines. This does not amount to general legalisation of non-medical use. Marketing authorisation, prescribing and safe use remain separate questions.
The accompanying data collection also has specific rules: the FOPH distinguishes, among other things, THC content and use within or outside an authorised indication. Records are stored in coded form. This is different from data being completely anonymous from the moment of collection.
Reimbursement: check the medicine and indication
A prescription alone does not establish an obligation for basic health insurance to pay. The particular medicine, its listing, the condition being treated and any restrictions matter. Exceptional reimbursement has additional requirements. Swissmedic authorisation and an insurer’s reimbursement decision are different matters.
Before treatment, it helps to clarify what the insurer confirms in writing, which services are covered and which costs could remain payable by the patient. No universal approval rate or fixed monthly cost can reliably be inferred.
Medicines are not interchangeable
An authorised finished medicine and an individually prepared formulation have different regulatory statuses. Research on one particular medicine does not automatically establish the same benefit for other products, even where both contain THC or CBD. A freely sold CBD product is not a substitute for a prescribed medicine.
Concentration, formulation, other medicines and the condition all affect treatment. This guide therefore gives no universal starting dose or instructions for increasing it independently. Adjustments belong in an individual plan agreed with the treating doctor.
If your prescribed preparation is unavailable, organise the questions for your pharmacy and treating team. Medical cannabis out of stock: next steps and discussing a medicine change
Safety and follow-up
Potential benefit needs to be weighed against adverse effects and interactions. Tiredness or dizziness can matter in daily life and during activities requiring alertness. Discuss other medicines, existing conditions, pregnancy or breastfeeding with the care team; a general list cannot replace the specific medicine’s prescribing information.
CBD medicines are not risk-free either. Swissmedic describes possible changes in liver test results with Epidyolex. Required monitoring depends on the medicine and treatment. An online article is not a reason to stop or alter existing medication.
Fitness to drive during treatment
If a person can demonstrate that THC comes from medication prescribed by a doctor, its presence alone does not establish unfitness to drive (Article 2(2ter) of the Swiss Traffic Rules Ordinance). Actual driving ability remains decisive. A prescription is therefore not blanket permission to drive.
Discuss possible effects on attention and reactions with your treating clinician. Do not drive while impaired, and take particular care when starting or changing treatment. Safety-sensitive tasks at work also need an individual assessment.
Clarify treatment goals and unanswered questions
A useful medical discussion starts with symptoms, previous treatments and a concrete goal: what change in everyday life would actually help? How will it be measured? When would insufficient benefit or an adverse effect argue against continuing?
The answers depend on the individual case. A guaranteed prescription, fixed waiting time or particular product’s availability cannot be promised generally. Shared decisions also need to address alternatives, costs, driving safety and planned follow-up.
Preparation overview: what is prescribed in Switzerland
Examples of different types of medicine. Prescribing information defines their precise use; this table is not a product recommendation.
| Preparation | Galenic form | THC | CBD | Primary indication |
|---|---|---|---|---|
| Sativex® | Oromucosal spray | Present | Present | Authorised additional treatment for defined MS-related spasticity; precise requirements in the prescribing information |
| Epidyolex® | Oral solution | Not the principal active ingredient | Active ingredient | Certain epilepsy syndromes; exact indication and age limits in the prescribing information |
| Individually prepared formulation | Depends on the prescription | Product-dependent | Product-dependent | Individual medical assessment; not equivalent to authorisation for every use |
Understanding evidence and authorisation
Authorisation and certainty of evidence answer different questions. These examples are neither a product ranking nor a general treatment recommendation.
| Condition | Assessment | Context assessed | Context and limitations |
|---|---|---|---|
| Chronic neuropathic pain | Low certainty of evidence | Cochrane review 2026 | Benefits and harms remain uncertain because evidence certainty is low; no extrapolation to every type of pain. |
| MS-related spasticity | Defined authorisation | Sativex authorisation | A defined additional treatment with specific requirements; not a finding about arbitrary cannabis products. |
| Certain epilepsy syndromes | Defined authorisation | Epidyolex authorisation | Medicine- and indication-specific assessment; not a recommendation for children to use retail CBD. |
Topic clusters & deep-dives
All medical content on CannabisClub — curated by indication, active compound, law and daily life:
Prepare questions for a medical appointment
Structured preparation supports a shared treatment decision.
- Define a goal: Describe symptoms and the change you would like in everyday life.
- Gather the background: Note previous treatments, other medicines and adverse effects.
- Discuss benefits and risks: Ask which evidence applies, what alternatives exist and which checks are needed.
- Clarify the decision and follow-up: Discuss costs, safety and criteria for assessing benefit later.
FAQ
Does a prescription prove that cannabis works for every condition?
No. Legal prescribing is not a general proof of effectiveness. Studies must match the medicine, condition and treatment goal.
How reliable is the evidence for neuropathic pain?
The 2026 Cochrane review generally rates the certainty of evidence as low to very low. It does not support a blanket claim that cannabis reliably relieves chronic nerve pain.
Does basic insurance automatically pay?
No. Prescribing and reimbursement are separate decisions. The medicine, indication, listing, restrictions and, where relevant, exceptional reimbursement requirements matter.
Is shop-bought CBD oil the same as a CBD medicine?
No. The label CBD does not establish marketing authorisation, a defined pharmaceutical composition or a medical indication.
Can I use a dose found online?
No. Dosing and adjustments depend on the medicine, condition and other medication, among other factors. They belong in the plan agreed with the treating doctor.
Are all treatment data collected anonymously?
The FOPH describes coded storage. Coding and complete anonymisation are different. Reporting requirements have exceptions relating to the medicine and its use.
Does my prescription also serve as a travel document?
Not automatically. Controlled medicines are subject to destination and transit-country rules. Schengen rules cannot be applied indiscriminately to the EU, EFTA or other countries.
May I drive while taking prescribed cannabis?
A prescription alone cannot answer that question. Where medically prescribed use is demonstrated, detecting THC does not by itself establish unfitness to drive. Driving while impaired remains prohibited. Discuss your individual circumstances with your treating clinician.
Primary sources & scientific literature
Selected official information and research. A source about one medicine cannot automatically be applied to all cannabis products.
- Traffic Rules Ordinance, Article 2(2ter) — medication and driving (German text) — Fedlex
- Prescribing and data collection — BAG / OFSP / UFSP / FOPH
- Types of medicine and treatment recommendations — BAG / OFSP / UFSP / FOPH
- Medicine reimbursement — BAG / OFSP / UFSP / FOPH
- Epidyolex: authorisation report and safety — Swissmedic
- Cannabis-based medicines for chronic neuropathic pain — Cochrane (2026)
- Travelling with controlled medicines — Swissmedic